The RAB7 gene (RAB7, member RAS oncogene family) encodes a member of the RAB family of small GTPases that is essential for endolysosomal trafficking, autophagosome maturation, and lysosomal function. As a key regulator of the late endocytic pathway, RAB7 coordinates membrane fusion events that are critical for cellular homeostasis, nutrient recycling, and protein quality control. In neurons, where intracellular transport over long distances is essential for synaptic function, RAB7 plays a particularly vital role in maintaining axonal and dendritic integrity.
RAB7 has emerged as a critical player in neurodegenerative disease pathogenesis. Mutations in RAB7 cause Charcot-Marie-Tooth disease type 2B (CMT2B), an autosomal dominant peripheral neuropathy characterized by distal muscle weakness and sensory loss. Additionally, RAB7 dysfunction has been implicated in Alzheimer's disease, Parkinson's disease, and Huntington's disease, where defects in autophagic flux and lysosomal function contribute to protein aggregate accumulation and neuronal death.
| | |
|---|---|
| **Gene Symbol** | RAB7 |
| **Full Name** | RAB7, member RAS oncogene family |
| **Chromosome** | 3q21.3 |
| **NCBI Gene ID** | [7409](https://www.ncbi.nlm.nih.gov/gene/7409) |
| **OMIM** | [602298](https://omim.org/entry/602298) |
| **Ensembl ID** | [ENSG00000075711](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000075711) |
| **UniProt ID** | [P51149](https://www.uniprot.org/uniprot/P51149) |
| **Protein Class** | Small GTPase (Rab family) |
| **Associated Diseases** | Charcot-Marie-Tooth disease type 2B, Alzheimer's disease, Parkinson's disease, Huntington's disease |
The human RAB7 gene spans approximately 11 kb and consists of 7 exons encoding a 207-amino acid protein with a molecular weight of approximately 23 kDa. Like other Rab GTPases, RAB7 contains conserved GTP-binding motifs (GxxxxGKST, DxxG, and NKXD) that enable cyclic GDP/GTP binding and hydrolysis. The protein undergoes post-translational geranylgeranylation at C-terminal cysteine residues, which facilitates membrane association.
RAB7 cycles between an active GTP-bound state and an inactive GDP-bound state, regulated by:
RAB7 is the master regulator of the late endocytic pathway. It controls:
Early-to-late endosome maturation: RAB7 recruitment to endosomes drives membrane remodeling and cargo progression toward degradation [1]
Late endosome-lysosome fusion: RAB7 on late endosomes interacts with lysosomal syntaxin17 and VAMP7 to mediate fusion events essential for cargo delivery to lysosomes [2]
Endolysosomal trafficking coordination: RAB7 works with the retromer complex to recycle proteins from endosomes back to the plasma membrane and trans-Golgi network [3]
RAB7 plays multiple critical roles in autophagy:
RAB7 is essential for lysosome maintenance:
RAB7 participates in mitochondrial dynamics and quality control:
RAB7 is ubiquitously expressed with particularly high levels in the nervous system:
CMT2B (OMIM #600882) is an autosomal dominant axonal peripheral neuropathy caused by RAB7 mutations. The disease is characterized by:
The pathogenesis involves toxic gain-of-function effects, where mutant RAB7 impairs endolysosomal trafficking, leads to accumulation of enlarged endosomes, and disrupts axonal integrity [8].
RAB7 dysfunction contributes to AD pathogenesis through multiple mechanisms:
RAB7 is implicated in PD through:
RAB7 dysfunction contributes to HD pathogenesis:
RAB7 represents a promising therapeutic target:
Lysosomal trafficking and function in health and disease. 2020. ↩︎
Retromer and RAB7 cooperate in endosomal trafficking. 2017. ↩︎
NRBF2 is a RAB7 effector required for autophagosome maturation. 2020. ↩︎
RAB7 and lysosome biogenesis. 2019. ↩︎
RAB7 in mitochondrial quality control and mitophagy. 2020. ↩︎
RAB7 mutations cause Charcot-Marie-Tooth disease type 2B. 2012. ↩︎
RAB7 in Parkinson's disease - autophagic flux and alpha-synuclein clearance. 2020. ↩︎
RAB7-mediated trafficking defects in Huntington's disease. 2021. ↩︎
TBC1D5 inhibition activates RAB7 and enhances retromer function. 2018. ↩︎
Vps41-mediated neuroprotection in Alzheimer's and Parkinson's models. 2018. ↩︎